rfk semaglutide An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup Makers of compounded Wegovy, Ozempic

The next frontier is GLP-1 pills, and so far, it looks like Novo may have an early lead once again: In clinical trials, people on the pill version of Wegovy lost an average of 16.6% of their body weight after 64 weeks, compared to Eli Lillys GLP-1 pill, Foundayo, which helped patients lose 12.4% of their body weight after 72 weeks

doi: 10.1016/j.ymgme.2020.10.003 [DOI] [PMC free article] [PubMed] [Google Scholar] 28

Henriques AD, Benedet AL, Camargos EF, Rosa-Neto P, Nbrega OT

With a background in healthcare and hospitality operations, business development, and patient relations, she has played an integral role in the growth of Lifestyle Health Services' medical weight loss and wellness programs